Lisa A. Carey, MD, and Sherene Loi, MD, PhD, on Immunotherapy for TNBC: IMpassion130 Results

Posted: Thursday, October 25, 2018

Sherene Loi, MD, PhD, of the Peter MacCallum Cancer Centre, and Lisa A. Carey, MD, of the University of North Carolina, discuss the phase III IMpassion 130 trial testing the first-line combination of the PD-L1 inhibitor atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.